Lindsay Fischer

An analysis of 141 children who had prenatal exposure to maternal cancer showed promising cognitive and behavioral functions at age 9 years.

Both the gastric and breast cancer HER2 scoring algorithms may be useful in determining which patients with metastatic colorectal cancer may derive benefit with tucatinib/ trastuzumab.

Patients with advanced hepatocellular carcinoma experienced similar health-related quality of life scores whether they received a combination of pembrolizumab and lenvatinib or lenvatinib and placebo.

There continues to be an unmet need for effective and tolerable frontline treatments for patients with squamous cell carcinoma of the head and neck, according to investigators.

A decision model with a 10-year time horizon found that nivolumab plus ipilimumab was the most effective combination for patients with metastatic renal cell carcinoma, but sunitinib was the most cost-effective approach.

Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.

Nilesh Kalariya, PhD, AGPCNP-BC, AOCNP, discusses key data of interest from the 2022 American Society of Hematology Meeting.

Laura J. Zitella, MS, RN, ACNP-BC, AOCN, highlights her top takeaways from the 64th American Society of Hematology Annual Meeting and Exposition.

For patients with head and neck cancer who cannot access full-dose checkpoint inhibitors, adding low-dose nivolumab to metronomic chemotherapy may represent an acceptable alternative treatment approach.

Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP, reflects on data presented at the San Antonio Breast Cancer Symposium.

Jamie Carroll, APRN, CNP, MSN, weighs in on how findings from the POSITIVE study may change dialogue surrounding pregnancy for women with estrogen receptor–positive breast cancer who wish to pause adjuvant therapy.

Cannabidiol oil may be useful in helping patients with breast cancer manage tamoxifen-related adverse effects.

An economic analysis showed that neither polatuzumab vedotin nor CD19-directed CAR T-cell therapy are likely to be the most cost-effective for patients with diffuse large B-cell lymphoma based on their high costs and current long-term survival estimates.

Loperamide prophylaxis was linked to low rates of grade 3 diarrhea in patients receiving adjuvant pyrotinib, but better antidiarrheal prophylaxis options are still needed in this setting.

Maintenance therapy with rucaparib monotherapy improved progression-free survival compared with placebo. However, the treatment also significantly elevated anemia and neutropenia rates in this setting.

Patients with early-stage, HER2-positive breast cancer who received both adjuvant ado-trastuzumab emtansine and concurrent radiotherapy did not experience a significant drop in ejection fraction or global longitudinal strain.

Black mulberry extract may help patients manage oral mucositis, dry mouth, and weight gain, while receiving oral cancer medications.

An ASCO/SIO expert panel outlined evidence supporting integrative therapies for adults. There is insufficient evidence in the pediatric population.

APRNs developed a discharge program which reduced readmission rates for patients receiving immunotherapy for advanced melanoma.

Patients with acute lymphoblastic leukemia who received vincristine-based regimens with TKIs did not experience more chemotherapy-induced peripheral neuropathy vs those who did not.

A nonrestrictive diet was found to be noninferior to a protective diet in the post-stem cell transplant setting, suggesting that lifting restrictions may improve patient quality of life.

In this episode of "The Vitals," Heather Jackson, PhD, FNP-BC, NEA-BC, FAANP, shares her experience helping a patient reduce their opioid use through acupuncture treatments.

Treatment with chemotherapy, including taxane-based chemotherapies, in the adjuvant setting did not yield significant differences in breast-cancer related lymphedema risk.

Adagrasib has received accelerated approval for KRAS G12C mutated non–small cell lung cancer. The prescribing label comes with warnings for gastrointestinal toxicities, QTC interval prolongation, hepatotoxicity, and interstitial lung disease.

Adding daratumumab to bortezomib, lenalidomide, and dexamethasone showed meaningful improvements in patient-reported outcomes in the phase 2 GRIFFIN trial.

Findings from the POSITIVE trial suggest that pausing endocrine therapy to pursue pregnancy did not negatively affect outcomes for patients with breast cancer.

New findings suggest that neoadjuvant therapy with antibody-drug conjugates may be effective for patients with early-stage breast cancer.

Osheka Hansel, APRN, discusses the recent approval of futibatinib (Lytgobi) for patients with unresectable, locally advanced or metastatic intrahepatic FGFR2-positive cholangiocarcinoma.

Adjuvant pembrolizumab demonstrated significantly better quality of life outcomes for patients with resected melanoma vs standard care.

The FDA has approved olutasidenib capsules to treat patients with relapsed or refractory acute myeloid leukemia with identified an IDH1-mutation. The label comes with a boxed warning for differentiation syndrome, and a warning for hepatotoxicity.